Variable | All patients (n = 208) | |
---|---|---|
No. | % | |
Age, years | ||
Median | 58 | |
Range | 29–82 | |
Sex | ||
Male | 136 | 65.4 |
Female | 72 | 34.6 |
Smoking status | ||
Current | 73 | 35.1 |
Former | 58 | 27.9 |
Never | 77 | 37.0 |
Histology | ||
Adenocarcinoma | 164 | 78.8 |
Squamous cell | 32 | 15.4 |
Other | 12 | 5.8 |
Stage | ||
IIIB | 15 | 7.2 |
IV | 193 | 92.8 |
ECOG PS | ||
0 | 17 | 8.2 |
1 | 134 | 64.4 |
2 | 57 | 27.4 |
First-line therapy | ||
GP | 105 | 50.5 |
IP | 103 | 49.5 |
Salvage EGFR-TKI therapy | ||
Second-line | 60 | 28.8 |
Third-line | 38 | 18.3 |
No | 110 | 52.9 |
EGFR mutations | ||
19DEL | 38 | 18.3 |
L858R | 13 | 6.3 |
Wild type | 143 | 68.7 |
Not determined | 14 | 6.7 |
KRAS mutations | ||
Codon 12 | 8 | 3.8 |
Codon 13 | 2 | 1.0 |
Codon 61 | 2 | 1.0 |
Wild type | 123 | 59.1 |
Not determined | 73 | 35.1 |